Our work highlights the importance of eIF4F in ALS/FTD pathogenesis, thereby opening the potential for new therapeutic strategies using existing eIF4F inhibitors to mitigate the effects of this neurodegenerative disease. This evidence concerns the gene EIF4G1 and frontotemporal dementia.